Breast cancer is one of the most prevalent cancers affecting women worldwide. It is a heterogeneous disease with various subtypes, one of which is HER2-negative breast cancer. HER-2 Negative Breast Cancer Market refers to tumors that do not overexpress the human epidermal growth factor receptor 2 (HER2), making it less responsive to targeted therapies. However, recent advancements in diagnostic tools have revolutionized the management and treatment of HER2-negative breast cancer.
Genomic profiling has emerged as a game-changer in cancer diagnostics. With the advent of next-generation sequencing (NGS) technologies, it is now possible to analyze the entire genome of cancer cells quickly and cost-effectively. In the case of HER-2 Negative Breast Cancer Market, genomic profiling enables molecular subtyping based on gene expression patterns. This approach allows for the identification of distinct subgroups within the HER2-negative population, each with unique biological characteristics and potential therapeutic targets. Molecular subtyping helps in tailoring treatment strategies and predicting treatment response, thereby improving patient outcomes.
Discover More- https://cmi-latestreportorientedblogs.blogspot.com/2023/06/her-2-negative-breast-cancer-market.html
Comments
0 comment